Comparison of the Effect on Blood Pressure Variability in acute ischemic stroke: Fimasartan vs. Valsarta
- Conditions
- Diseases of the nervous system
- Registration Number
- KCT0003254
- Lead Sponsor
- Gachon University Gil Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 80
• Adults older than 30
• Patients with acute ischemic stroke who have symptoms described by diffusion weighted image and who are within 28 days after onset 7
• Patients whose screening systolic blood pressure is greater than 140 mmHg or who are taking antihypertensive drugs
• If the neurological deterioration stabilizes during screening and more than 48 hours have elapsed
• Hemorrhagic stroke patients
• Patients with somatic hypotension
• Severe stroke patients - Patients with a NIHSS (NIH Stroke Scale) score of 16 or greater
• Patients whose mean blood pressure during screening was not adjusted to more than 200 mmHg
• Patients allergic to hypertensive drugs
• Hematologic tests show abnormalities such as:
- Abnormal liver function abnormalities (SGOT, SGPT, total bilirubin, if more than twice the normal value)
- Anemia (hemoglobin <8mg / dl) or thrombocytopenia (<100,000 / mm3)
- kidney failure (serum creatinine> 2.0 mg / dl)
• Patients who are pregnant or lactating
• Patients with suspected secondary hypertension
• Patients that researchers consider inappropriate
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method difference of mean and standard deviation of the entire 24-h period and separately for the daytime period and the nighttime period between two groups after treatment, which is measured by ambulatory blood pressure monitoring.
- Secondary Outcome Measures
Name Time Method difference of other parameters for blood pressure variability such as weighted standard deviation, coefficient of variation, average real variability. Primary and secondary outcomes were evaluated at baseline and 8 weeks